Aranesp: The heart of the matter

Prolonged anemia can lead to serious heart disease, providing a rationale for using drugs that stimulate red blood cell production to improve cardiovascular outcomes. Yet this hasn't been tested in practice until now. Last week, Amgen Inc. said it had begun a Phase III trial of its Aranesp darbapoetin to study the impact of

Read the full 542 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE